alexa The Balance Of Cellular And Humoral Immunity Determines The Level Of Protection Offered By A HIV Vaccine In Macaque Models Of HIV Infection
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Timothy Fouts
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
O btaining a practical, efficacious vaccine against HIV has been a public health priority for over 30 years. A guiding principle for vaccine design has been that cellular and humoral immunity will work together to provide the strongest level of efficacy. This concept has been called into question after the failure of several large clinical trials, giving rise to the ideas that vaccine-induced immune responses may not act in concert and might even increase risk by immune activation, thereby providing more targets for infection. We have addressed this issue through a series of nonhuman primate studies using a selected HIV/SIV envelope-based subunit antigen, called the Full-length Single Chain (FLSC). The FSLC was developed in order to induce broader immunity, including against new conserved epitopes, compared to conventional gp120. Here, we tested the FLSC in a variety of formulations and vaccination regimens that generated a variety of immune response profiles. We used two repeat low dose challenge models (heterologous SHIV (162P3) and cross-clade SIVmac251) to test for protection in three separate studies. Under certain conditions, immunization with the FLSC was able to protect against heterologous neutralization resistant challenge viruses in all three studies. The data show that antibody dependent cellular cytotoxicity (ADCC) is associated with a reduced rate of acquisition against repeat challenges with either challenge virus provided that the concurrent anti-vaccine T cell response is minimal. Protection is lost over time as requisite antibody titers declined consistent with the evanescent quality of anti-envelope humoral responses. Vaccine efficacy was consistently lost in animals exhibiting higher T cell responses that were predominately single or dual function. These data indicate that in the case of HIV the balance between the humoral immune response and cellular immune activation is the critical element for generating protective efficacy. Achieving and sustaining such a balance, while enhancing antibody durability, is a significant challenge for HIV vaccine development
Timothy Fouts is one of the founders and principle scientists at Profectus Biosciences. He directs a team of scientists in the discovery and preclinical development of vaccines, small molecule and antibody based antiviral therapies and microbicides that are within the Profectus research portfolio, in particular HIV and certain biothreat viruses. He has more than 32 scientific publications that have appeared in peer-reviewed journals and book chapters. He received his PhD in Immunology from the University of Maryland, Baltimore and did a Postdoctoral fellowship at the Aaron Diamond AIDS Research Center at Rockerfeller University in NYC
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version